Drugs / STP1002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04505839 | Jul 2020 → Mar 2023 | neoplasm | ST Pharm Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-03-16 | ST Pharm Co., Ltd. | Results [안내] 에스티팜 2023 AACR 학회 발표 논문 초록 게재 stpharm.co.kr ↗
Dual combination of STP1002 and MEK inhibitor synergistically reduced the oncogenic activity of KRAS (G12V or G12D)-mutated CRC cell lines. |
| 2020-04-01 | ST Pharm Co., Ltd. | Regulatory 에스티팜, 대장암 신약 후보물질 미국 FDA 임상1상 계획 승인 stpharm.co.kr ↗ |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-03-23 | ST Pharm Co., Ltd. | [안내] 항암제 STP1002 WHO에 Basroparib 국제일반명 등재 stpharm.co.kr ↗ |
| 2023-03-16 | ST Pharm Co., Ltd. | [안내] 에스티팜 2023 AACR 학회 발표 논문 초록 게재 stpharm.co.kr ↗ |
| 2023-03-09 | ST Pharm Co., Ltd. | [안내] 에스티팜 2023 AACR 학회 참석, STP1002 항암제 병용투여 전임상 결과 공개 stpharm.co.kr ↗ |
| 2022-07-18 | ST Pharm Co., Ltd. | [안내] 에스티팜 항암제 STP1002, 전임상 결과 논문 국제학술지 게재 stpharm.co.kr ↗ |
| 2020-04-01 | ST Pharm Co., Ltd. | 에스티팜, 대장암 신약 후보물질 미국 FDA 임상1상 계획 승인 stpharm.co.kr ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STP1002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04505839 ↗ |
| Route | Oral | “Oral capsule, QD” NCT04505839 ↗ |